Allogene Therapeutics Inc. 宣布,计划在2026年第二季度初对其Alpha3二期临床试验中微小残留病(MRD)清除率的数据进行一项中期无效性分析。该分析旨在评估试验的继续价值,是药物研发过程中的一个关键节点。
Allogene Therapeutics Inc. 宣布,计划在2026年第二季度初对其Alpha3二期临床试验中微小残留病(MRD)清除率的数据进行一项中期无效性分析。该分析旨在评估试验的继续价值,是药物研发过程中的一个关键节点。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.